INTRODUCTION AND OBJECTIVES:
We assessed the outcomes of the patients with pT0 on first protocol biopsy during active surveillance (AS) from the analysis Japanese cohort forming part of the Prostate Cancer Research International: Active Surveillance (PRIAS) study.
METHODS: PRIAS-JAPAN started in January 2010. 39 institutions are participating in this study, and the Institutional Review Boards of the participating centers have approved the study protocol. The inclusion criteria for the PRIAS study are as follows: clinical stage T1c/T2, PSA 10 ng/ml, PSA density (PSAD) < 0.2 ng/ml per milliliter, one or two positive biopsy cores, and Gleason score (GS) 6 at initial diagnostic biopsy. Pathological reclassification is defined as the deviation of pathological findings on re-biopsy from the inclusion criteria.
In this analysis, we defined the patients presenting no reclassification with cancer after first protocol biopsy as NR-CA group and the patients presenting no reclassification showing pT0 as NR-noCA group. We compared AS remaining rate, pathological outcomes in extra biopsy and second protocol biopsy at 4 years between two groups. RESULTS: First protocol biopsy was performed on 514 patients. 191 patients were in NR-noCA group and 199 patients were in NR-CA group. Patients background of NR-noCA group was as follows: Median age was 68, median PSA was 5.6ng/ml, and median prostate volume was 38.4cc. T1c were in 183 and T2a were in 8. At the time of first protocol biopsy, there was no significant differences about PSA parameters and pathological factors between NR-noCA group and NR-CA group. Also, extra biopsy performing rate (NRnoCA group vs NR-CA group; 5.75% vs 7.53%)and implementation rate of second protocol biopsy at 4 years (75.6% vs 63.6%)showed no significant differences. On second protocol biopsy, number of cancer positive cores were significantly smaller and rate of pT0 was higher in NR-noCA group. After five years, both group showed comparable AS remaining rate (76.9 vs 75.3%). Thirty eight patients of NR-noCA group selected definitive therapy and surgery was the most frequently chosen treatment option.
CONCLUSIONS: Although rate of pT0 on second biopsy was higher in NR-noCA group, there was no significant difference between both groups in AS remaining rate. The patients in NR-noCA group tended to choose surgery as a definitive therapy. METHODS: On our database of 700 RARP, we retrospectively analyzed 80 pt with LR-PCa with a median Follow Up (FU) of 18 months (range 12-36). We included only pt with cT1c, GS <6, PSA <10 ng/ml, potentially eligible to AS according to recent evidences, with a BOO pattern at Uroflowmetry (UF) (Fmax <15 ml/s) and IPSS (>8). After cognitive fusion biopsy all pt underwent fNSRARP according to PERUSIA technique, with urethral maximization. Pt >70 yr, diabetic, with apical disease, prostate <50 gr, non sexual activity and with a FU <12 months were excluded. An age-matched cohort of 20 pt with comparable prostate volume who underwent HoLEP was recruited as a control group. All pt underwent UF, Uroflow Stop Test (UST), IPSS, ICS, IIEF-5 score preoperatively and at 12 months. Complications evaluated according to Clavien Dindo. Urinary Incontinence was assessed through UST at 12 months and direct interview (question number 5 of EPIC questionnaire). Positive UST test, and no pad use identify fully continent pt, the others were considered as incontinent. Potency was achieved when IIEF-5 was >17, with or without oral drug. Student T and Chi-square tests (SPSSÒsoftware) were used with a significance level <0.05.
Source of
RESULTS: Table shows our results. Median catheterization time and hospital stay were 7 days (range 6-14) and 2 days (range 1-12); overall complications' rate was 25% (20) and 10% (2) respectively in the two groups. No major complications occurred. Positive surgical margin rate was 15% (12 pt), with upgrading occurred in 21pt (26,2%) . No pt needed Radiotherapy. Pentafecta rate was 65% (48 pt). No statistical differences were detected between the two groups for studied parameters.
CONCLUSIONS: Management of obstructed pt during AS is far to be determined and urologists must inform pt before choosing clinical strategy for LR-PCa. Beyond the good pentafecta rate, fNSRARP allows to achieve a BOO resolution at 1 year comparable to pt undergoing HoLEP. Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e1015
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